Clínic Hospital

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Head of the Cardiology Department at the Hospital Clínic de Barcelona and researcher at the National Centre for Cardiovascular Research (CNIC) and at the August Pi Sunyer Biomedical Research Institute (IDIBAPS)

Scientific Director of the Centre for Biomedical Research in Mental Health Network (CIBERSAM). Head of the Psychiatry and Psychology Department at the Hospital Clínic de Barcelona and lecturer at the University of Barcelona

Professor of Medicine at the University of Barcelona and coordinator of the Central Sensitisation Unit at the Hospital Clínic de Barcelona.

Head of the HIV-AIDS unit, Hospital Clínic-Barcelona

Head of the Immunology Service

Neurologist leader of the Neuroimmunology group at IDIBAPS - Hospital Clínic and adjunct professor at Stanford University.

Head of the Neurology Department at Hospital Clínic de Barcelona and secretary of the Spanish Society of Neurology's Study Group on Behaviour and Dementia

Contents related to this centre

Swedish research involving more than 6,000 male footballers in the country's top division (between 1924 and 2019) indicates that they were 1.5 times more likely to develop a neurodegenerative disease compared to the population analysed who were not involved in professional football. Unlike outfield players, goalkeepers did not have this increased risk, which, according to the authors, supports the hypothesis that impacts to the head when striking the ball could explain the increased risk. The study is published in The Lancet Public Health.


A virological and immunological follow-up confirms that a third patient has been cured of HIV nine years after receiving a bone marrow transplant for myeloid leukaemia, and four years after stopping his antiretroviral treatment. This case of the Düsseldorf patient, similar to two previously documented in Berlin and London, is detailed in a Nature Medicine publication by an international consortium coordinated by the IrsiCaixa AIDS Research Institute and the University Medical Center in Utrecht, the Netherlands. The patient was diagnosed with HIV in 2008 and in 2011 with leukaemia, for which he received the transplant in 2013.


Two studies have found changes in the microbiome of patients affected by chronic fatigue syndrome. In particular, they have found a decrease in both butyrate and certain bacteria that produce butyrate. Butyrate is a factor related to the protection of the intestinal barrier and appears to play a role in the regulation of the immune system. Both papers are published in the journal Cell Host and Microbe.


A Swedish study has found an association between lack of sleep or poor quality sleep during adolescence and an increased risk of developing multiple sclerosis later in life. They put the relative increased risk at 40 %. The results are published in the Journal of Neurology, Neurosurgery and Psychiatry.


Procrastination in a sample of more than 3,500 students was associated with the development of both mental and physical health problems nine months later, according to a study conducted at several universities in Sweden. The results are published in the journal JAMA Network Open.


Two preclinical studies published in the journal Science have introduced new bioengineered modifications to CAR-T cells in an attempt to make them more potent and safer in their anti-tumour action. These variations allow their activity to be enhanced only in the vicinity of the tumour or their actions to be regulated on demand.


Two studies published in the journal Nature Communications have found specific characteristics in the microbiota of people with depression, including populations of different ethnicities and habits.


A few weeks ago, a press release from the Biogen and Eisai companies reported significant results from their lecanemab antibody for the treatment of early-stage Alzheimer's. The data from the phase 3 trial are now published in the New England Journal of Medicine, coinciding with the CTAD conference on Alzheimer's disease clinical trials in San Francisco. Data from the phase 3 clinical trial are now published in the New England Journal of Medicine, coinciding with the 15th CTAD Alzheimer's disease clinical trials conference in San Francisco.


A pioneering phase 1 clinical trial has tested a type of cancer immunotherapy. Researchers have modified patients' own T-lymphocyte receptors using the CRISPR tool to direct them against specific targets on their own tumours. The results are published in the journal Nature.


A phase 2 clinical trial has examined the use of the hallucinogen psilocybin in different amounts for the treatment of resistant depression. The results are published in the New England Journal of Medicine.